Longeveron (LGVN) Notes Payables (2021 - 2023)

Longeveron (LGVN) recorded quarterly Notes Payables of $457000.0 in Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.

Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends

Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.

  • In Q1 2023, Notes Payables changed N/A year-over-year to $457000.0; the TTM figure through Mar 2023 stood at $457000.0 (changed N/A YoY), while the FY2022 annual figure was $1.8 million, up 171.47% from the prior year.
  • Notes Payables was $457000.0 for Q1 2023 at Longeveron, down from $1.8 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.8 million in Q4 2022 to a low of $457000.0 in Q1 2023.
  • Historically, Notes Payables has averaged $951000.0 across 3 years, with a median of $645000.0 in 2021.
  • Biggest YoY gain for Notes Payables was 171.47% in 2022; the steepest drop was 171.47% in 2022.
  • A 3-year view of Notes Payables shows it stood at $645000.0 in 2021, then jumped by 171.47% to $1.8 million in 2022, then slumped by 73.9% to $457000.0 in 2023.
  • The last three Notes Payables figures came in at $457000.0 (Q1 2023), $1.8 million (Q4 2022), and $645000.0 (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00

Historic Data

Download Data
DateValue
Mar 31, 2023 457,000.00
Dec 31, 2022 1.75 Mn
Dec 31, 2021 645,000.00